Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Hereditary Angioedema · Diabetic Macular Edema · KALV

Kalvista Pharmaceuticals (Ireland)

Kalvista Pharmaceuticals (Ireland) Limited

Kalvista Pharmaceuticals (Ireland) patent portfolio — 24 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Framingham, USA HQ
279 Employees
Public company Type
KALV · NYSE Ticker
Company details
Status
Public
HQ
Framingham, USA
Employees
279
Programs
8
Drugs
6
Patents
24
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Kalvista Pharmaceuticals (Ireland) patents

24 pharmaceutical patents indexed for Kalvista Pharmaceuticals (Ireland). 0 expire within 24 months.

Kalvista Pharmaceuticals (Ireland) has 24 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

24 patents

Patent portfolio

  1. US 11739068

    Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof

    Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11613527

    Enzyme inhibitors

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11584735

    Solid forms of a plasma kallikrein inhibitor and salts thereof

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11242333

    Inhibitors of plasma kallikrein

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11234939

    Dosage forms comprising a plasma kallikrein inhibitor

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11230537

    Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11198691

    N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11180484

    Pyrazole derivatives as plasma kallikrein inhibitors

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11084809

    N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11001578

    N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10781181

    N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10752607

    Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10611758

    N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10478409

    Pharmaceutical compositions

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10364238

    N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10221161

    Inhibitors of plasma kallikrein

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9849100

    Pharmaceutical compositions suitable for parenteral administration comprising aqueous suspensions of benzylamine derivatives having low solubilities

    Expires Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9834513

    Benzylamine derivatives

    Expires Mon Nov 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9738641

    Bicyclic inhibitors

    Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9670157

    Benzylamine derivatives

    Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9533987

    Heterocyclic derivates

    Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9512065

    Polymorphs of N-[(R)-1-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9234000

    Benzylamine derivatives as inhibitors of plasma kallikrein

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9051249

    Benzylamine derivatives as inhibitors of plasma kallikrein

    Expires Mon Jun 04 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Kalvista Pharmaceuticals (Ireland) have?

24 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Kalvista Pharmaceuticals (Ireland) patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.